A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders.
Multiple Sclerosis and Related Disorders(2020)
Abstract
•First, tocilizumab significantly decreased the ARR ratio and relapse rate of NMOSD.•Second, tocilizumab therapy is safe for patients with NMOSD.•Third, the study found that tocilizumab therapy did not have a significant effect on EDSS score. Larger sample size and long duration of treatments are expected to assess effect on EDSS score in future.
MoreTranslated text
Key words
Neuromyelitis optica spectrum disorders,Tocilizumab,Meta-analysis,Efficacy,Safety
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined